# ECOG-ACRIN E2408 (NCT01216683)

> Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

No report yet. It can be ordered.

- Drugs tested: bortezomib; lenalidomide
- Indication: high-risk untreated follicular lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01216683
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: ECOG-ACRIN Cancer Research Group
- Conditions: Lymphoma
- Interventions: rituximab; Bendamustin; bortezomib; lenalidomide
- Enrollment: 289
- Primary outcome: Complete Remission (CR) Rate
- Primary outcome: 1-year Post-induction Disease-free Survival (DFS) Rate

## Indexed commentary on ECOG-ACRIN E2408 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 5 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=ecog-acrin-e2408-nct01216683
